145 related articles for article (PubMed ID: 30639534)
1. Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.
Bianchini F; Portioli E; Ferlenghi F; Vacondio F; Andreucci E; Biagioni A; Ruzzolini J; Peppicelli S; Lulli M; Calorini L; Battistini L; Zanardi F; Sartori A
Cancer Lett; 2019 Apr; 446():25-37. PubMed ID: 30639534
[TBL] [Abstract][Full Text] [Related]
2. Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools.
Bianchini F; De Santis A; Portioli E; Russo Krauss I; Battistini L; Curti C; Peppicelli S; Calorini L; D'Errico G; Zanardi F; Sartori A
Nanomedicine; 2019 Jun; 18():135-145. PubMed ID: 30849548
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the α
Sartori A; Portioli E; Battistini L; Calorini L; Pupi A; Vacondio F; Arosio D; Bianchini F; Zanardi F
J Med Chem; 2017 Jan; 60(1):248-262. PubMed ID: 27997164
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
6. JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin αvβ3 signaling.
Cui J; Shu C; Xu J; Chen D; Li J; Ding K; Chen M; Li A; He J; Shu Y; Yang L; Zhang R; Zhou J
Theranostics; 2020; 10(18):8036-8050. PubMed ID: 32724456
[No Abstract] [Full Text] [Related]
7. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
[TBL] [Abstract][Full Text] [Related]
8. Conformation-dependent binding of a Tetrastatin peptide to α
Lambert E; Fuselier E; Ramont L; Brassart B; Dukic S; Oudart JB; Dupont-Deshorgue A; Sellier C; Machado C; Dauchez M; Monboisse JC; Maquart FX; Baud S; Brassart-Pasco S
Sci Rep; 2018 Jun; 8(1):9837. PubMed ID: 29959360
[TBL] [Abstract][Full Text] [Related]
9. [Study of motogenic signal in human melanoma cells].
Kenessey I
Magy Onkol; 2011 Mar; 55(1):55-8. PubMed ID: 21617791
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Gowda R; Sharma A; Robertson GP
Cancer Lett; 2017 Jan; 385():243-250. PubMed ID: 27769779
[TBL] [Abstract][Full Text] [Related]
12. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
Li X; Li Z; Li X; Liu B; Liu Z
BMC Cancer; 2017 May; 17(1):357. PubMed ID: 28532456
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
15. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
16. Transient receptor potential cation 3 channel regulates melanoma proliferation and migration.
Oda K; Umemura M; Nakakaji R; Tanaka R; Sato I; Nagasako A; Oyamada C; Baljinnyam E; Katsumata M; Xie LH; Narikawa M; Yamaguchi Y; Akimoto T; Ohtake M; Fujita T; Yokoyama U; Iwatsubo K; Aihara M; Ishikawa Y
J Physiol Sci; 2017 Jul; 67(4):497-505. PubMed ID: 27613608
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.
Oudart JB; Doué M; Vautrin A; Brassart B; Sellier C; Dupont-Deshorgue A; Monboisse JC; Maquart FX; Brassart-Pasco S; Ramont L
Oncotarget; 2016 Jan; 7(2):1516-28. PubMed ID: 26621838
[TBL] [Abstract][Full Text] [Related]
18. Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models.
Skobowiat C; Oak AS; Kim TK; Yang CH; Pfeffer LM; Tuckey RC; Slominski AT
Oncotarget; 2017 Feb; 8(6):9823-9834. PubMed ID: 28039464
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
